狂犬病暴露后预防用单克隆抗体临床开发进展综述
狂犬病每年仍导致数万人死亡,暴露后预防需联合伤口清洗、疫苗和狂犬病免疫球蛋白。传统免疫球蛋白来自马或人血浆,存在供应、成本和质量局限。重组DNA技术生产的单克隆抗体可能克服这些局限,首个抗狂犬病单克隆抗体已在印度获批,多个候选产品正在临床试验中,WHO免疫策略咨询专家组已将其纳入2018年4月更新的狂犬病免疫政策建议。本文综述了抗狂犬病单克隆抗体的临床试验开发现状及血源性免疫球蛋白的历史临床试验路径,并讨论了临床评价、监管审批、采纳和监测方面的挑战。
要点
- 狂犬病暴露后预防需及时伤口清洗、接种疫苗和注射狂犬病免疫球蛋白。
- 传统狂犬病免疫球蛋白来自马或人血浆,存在供应、成本和质量局限。
- 首个抗狂犬病单克隆抗体已在印度获批,多个候选产品正在临床试验中。
核心结论
- 重组DNA技术生产的单克隆抗体可能克服传统狂犬病免疫球蛋白在供应、成本和质量方面的局限。
研究设计与样本
- 本文为综述,检索并汇总了抗狂犬病单克隆抗体的临床试验开发现状及血源性狂犬病免疫球蛋白的历史临床试验路径。
主要发现
- 首个抗狂犬病单克隆抗体已在印度获得监管批准,多个其他候选产品正在临床试验中评估。
- WHO免疫策略咨询专家组已考虑狂犬病单克隆抗体,并纳入2018年4月更新的WHO狂犬病免疫政策建议。
关键数值与推荐
- WHO免疫策略咨询专家组已将狂犬病单克隆抗体纳入2018年4月更新的WHO狂犬病免疫政策建议。
临床怎么用
- 临床可关注单克隆抗体作为狂犬病暴露后预防中狂犬病免疫球蛋白替代品的开发进展与监管动态。
局限性
- 本文为综述,未报告原始研究的具体样本量、效应值或统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite successful control in many parts of the world, rabies virus continues to result in tens of thousands of deaths each year. Death from rabies can be prevented by timely and appropriate post exposure prophylaxis including wound cleaning and administration of vaccine and rabies immunoglobulin. Currently, rabies immunoglobulin is derived from the blood plasma of horses or humans and has several limitations relating to supply, cost and quality. Monoclonal antibodies produced through recombinant DNA technologies could potentially overcome these limitations. The first anti-rabies monoclonal antibody has recently gained regulatory approval in India and there are several other candidates being evaluated in clinical trials. Given the advances in the field, rabies monoclonal antibodies have been recently considered by the World Health Organization's Strategic Advisory Group of Experts on Immunization and included in updated WHO immunization policy recommendations for rabies published in April 2018. This article reviews the current landscape of the clinical trial development of anti-rabies monoclonal antibodies and the historical clinical trial pathways followed for blood-derived rabies immunoglobulin before discussing challenges in the clinical evaluation, regulatory approval, uptake and monitoring of these products.
引用
- Sparrow E, Torvaldsen S, Newall AT, et al. Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline. Vaccine. 2018. PMID: 30503659. doi:10.1016/j.vaccine.2018.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。